EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis

Xianghong Wang, Rong Lin, Chuanchuan Sun, Niujian Wu, Hongyun Lu

Organ Medicine · 2025

DOI: 10.1002/orm2.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organ Medicine, 2025. Verfasst von Xianghong Wang und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As a member of the liprin‐α family of proteins, the functional relevance of PPFIA3 in cancer remains unclear. We aim to evaluate the role of PPFIA3 in pan‐cancer.

Methods

A large amount of RNA‐seq data was obtained from the TCGA and GTEx databases, using databases such as TISIDB, TIMER, cBioPortal, GEPIA2, HPA, CancerSEA, CellMiner, UALCAN, STRING, Sangerbox, Kaplan–Meier Plotter, and TISMO to analyze the correlation of PPFIA3 expression with tumor prognosis, immune infiltration levels, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), methylation levels, immune therapy, drug sensitivity, and so forth.

Results

PPFIA3 expression is commonly elevated in most cancers and is associated with poor prognosis. Furthermore, high PPFIA3 expression significantly correlates with immune regulatory genes, immune checkpoints, TMB, MSI, and methylation status. Additionally, PPFIA3 expression is associated with immune cell composition and infiltration levels. Interestingly, in patients receiving anti‐PD‐L1 therapy, high PPFIA3 expression is associated with improved survival and prognosis. Further analysis suggests that PPFIA3 can serve as a predictive factor for responsiveness to immune checkpoint blockade therapy in breast cancer. Moreover, our results indicate a strong correlation between PPFIA3 and drug sensitivity.

Conclusions

This pan‐cancer study provides a comprehensive understanding of the critical role of PPFIA3 in human cancer and suggests that PPFIA3 may be a potential prognostic biomarker and therapeutic target for cancer immunotherapy.

Zitieren

APA

Wang, X., Lin, R., Sun, C., Wu, N., & Lu, H. (2025). Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis. Organ Medicine. https://doi.org/10.1002/orm2.70008

Vancouver

Wang X, Lin R, Sun C, Wu N, Lu H. Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis. Organ Medicine. 2025. doi:10.1002/orm2.70008

BibTeX
@article{Wang2025,
  author = {Wang, Xianghong and Lin, Rong and Sun, Chuanchuan and Wu, Niujian and Lu, Hongyun},
  title = {Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis},
  journal = {Organ Medicine},
  year = {2025},
  doi = {10.1002/orm2.70008}
}
Kostenlos starten →